12:00 AM
 | 
May 14, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Dalcetrapib: Development discontinued

Roche discontinued development of cardiovascular compound dalcetrapib due to a "lack of clinically meaningful efficacy" in a second interim analysis of the double-blind, placebo-controlled, international Phase III dal-OUTCOMES trial in >15,000 patients with stable CHD following a recent acute coronary syndrome (ACS). The pharma made the decision based on a recommendation from the study's DSMB, which said that once-daily 600 mg oral dalcetrapib plus standard of care would not show a 15% reduction on...

Read the full 346 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >